Orelabrutinib obtained NMPA approval for treating R/R MZL in China

It is the first and the only approved BTK inhibitor for the treatment of R/R MZL in China

MZL is the second most common lymphoma in China, accounting for about 8.3 percent of total cases and mainly affecting middle-aged and elderly people

“MZL is considered incurable at the relapsed/refractory stage with limited therapeutic options. Orelabrutinib demonstrated a high response with durable disease remission and was well tolerated in Chinese patients with r/r MZL. The results of this study support the use of orelabrutinib as an effective and tolerable oral treatment option for r/r MZL patients” Jun Zhu, Professor of the Peking University Cancer Hospital